Exelixis logged a -8.7% change during today's afternoon session, and is now trading at a price of $19.28 per share. On average, analysts give it a target price of $25.76.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The mid-cap company is based in the United States.
What to Consider if You Are Thinking of Buying Exelixis:
-
Exelixis has moved 18.0% over the last year.
-
EXEL has a forward P/E ratio of 20.7 based on its EPS guidance of 0.93.
-
Over the last 6 years, earnings per share (EPS) have been growing at a compounded average rate of 2.3%.
-
The company has a price to earnings growth (PEG) ratio of 0.66.
-
Its Price to Book (P/B) ratio is 2.44
Exelixis Has Irregular Cash Flows
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-07 | 362,614 | -27,706 | 390,320 | -14.22 |
| 2022-02-18 | 400,804 | -54,225 | 455,029 | 90.13 |
| 2021-02-11 | 208,982 | -30,345 | 239,327 | -55.66 |
| 2020-02-25 | 526,956 | -12,834 | 539,790 | 20.3 |
| 2019-02-22 | 415,720 | -32,989 | 448,709 | 140.48 |
| 2018-02-26 | 165,611 | -20,979 | 186,590 |
Exelixis's free cash flows have a decent average of $376.63 Million over the last 6 years, but they are highly variable since their coefficient of variability is 452305452.2%. The compounded average growth rate over this period is 0.0%.
